41. Elektrokemoterapija pri zdravljenju raka in genska imunoterapija pri bazalno celičnem karcinomu : klinična študija faze IGregor Serša, Maja Čemažar, 2023, objavljeni znanstveni prispevek na konferenci Povzetek: Elektrokemoterapija je lokalna ablativna terapija, ki temelji na uporabi elektroporacije, kot dostavnega sistema za citostatika bleomicin ali cisplatin. Njena uporaba je predvsem za zdravljenje kožnih tumorjev, kot so kožne metastaze melanoma ali bazalno celični karcinomi. Elektrokemoterapija je v smernicah mnogih evropskih držav. Učinkovitost elektrokemoterapije je v povprečju za vse vrste kožnih tumorjev, 86% objektivnih odgovorov (OR) in 71% popolnih odgovorov (CR) po enkratni terapiji. Za zdravljenje so objavljeni standardizirani postopki, na voljo je več certificiranih generatorjev električnih pulzov in različni tipi elektrod. Obstajajo pa razlike v stopnji odgovorov med različnimi tumorji. Bazalno celični so najbolj občutljivi, melanomski tumorji pa manj. Klinični napovedni dejavniki so zato vrsta tumorjev, ter velikost tumorjev in predhodna zdravljenja. Nedavne študije so dokazale sinergizem njenega delovanja z zaviralci imunskih kontrolnih točk pri bolnikih z melanomom. Na bazalno celičnem karcinomu se izvaja tudi faza I kliničnega preskušanja, katerega namen je preučiti varnost in sprejemljivost zdravila za gensko terapijo, plazmida phIL12. Ključne besede: rak kože, melanom, elektrokemoterapija Objavljeno v DiRROS: 18.05.2023; Ogledov: 219; Prenosov: 91 Celotno besedilo (511,65 KB) Gradivo ima več datotek! Več... |
42. Nižje število cirkulirajočih tumorskih celic v poznih linijah razsejanega raka dojkSilvester Jernej, Klara Geršak, Marina Mencinger, Tanja Ovčariček, Tanja Jesenko, Živa Modic, Simona Miceska, Maja Čemažar, Veronika Kloboves-Prevodnik, Cvetka Grašič-Kuhar, 2022, objavljeni povzetek strokovnega prispevka na konferenci Ključne besede: onkologija, rak dojke, kemoterapija Objavljeno v DiRROS: 03.02.2023; Ogledov: 421; Prenosov: 116 Celotno besedilo (45,75 KB) |
43. Morfološke značilnosti cirkulirajočih tumorskih celic raka dojk v krvi po izolaciji na podlagi njihovih fizikalnih ali bioloških lastnostiSimona Miceska, Tanja Jesenko, Živa Modic, Cvetka Grašič-Kuhar, Maja Čemažar, Urška Matkovič, Jerneja Varl, Anamarija Kuhar, Veronika Kloboves-Prevodnik, 2022, objavljeni povzetek znanstvenega prispevka na konferenci Ključne besede: citologija, diagnostika, onkologija Objavljeno v DiRROS: 27.01.2023; Ogledov: 417; Prenosov: 117 Celotno besedilo (241,64 KB) |
44. Učinkovitost elektrokemoterapije pri bolnicah z rakom dojke z različnim hormonskim statusom : izkušnje INSPECT skupineMarija Snežna Paulin-Košir, Claudia Di Prata, Eva-Maria Grischke, Giuseppe Azzarello, Julie Gehl, Francesca De Terlizzi, Gregor Serša, Maja Čemažar, 2022, objavljeni povzetek strokovnega prispevka na konferenci Ključne besede: onkologija, rak dojke, kemoterapija Objavljeno v DiRROS: 27.01.2023; Ogledov: 320; Prenosov: 84 Celotno besedilo (39,29 KB) |
45. Radiation induced upregulation of DNA Sensing pathways is cell-type dependent and can mediate the off-target effectsTanja Jesenko, Maša Omerzel, Boštjan Markelc, Gregor Serša, Katarina Žnidar, Loree C. Heller, Maja Čemažar, 2020, izvirni znanstveni članek Ključne besede: DNA sensors, irradiation, immunostimulation Objavljeno v DiRROS: 10.10.2022; Ogledov: 457; Prenosov: 243 Celotno besedilo (5,84 MB) Gradivo ima več datotek! Več... |
46. Bleomycin concentration in patientsʹ plasma and tumors after electrochemotherapy : a study from InspECT GroupAleš Grošelj, Maša Omerzel, Mojca Kržan, Tina Kosjek, Krisztina Bottyán, Helena Plešnik, Črt Jamšek, Maja Čemažar, Erika Kis, Gregor Serša, 2021, izvirni znanstveni članek Ključne besede: electrochemotherapy, electroporation, bleomycin Objavljeno v DiRROS: 10.10.2022; Ogledov: 488; Prenosov: 236 Celotno besedilo (670,54 KB) Gradivo ima več datotek! Več... |
47. Combination of pembrolizumab with electrochemotherapy in cutaneous metastases from melanoma : a comparative retrospective study from the InspECT and Slovenian Cancer RegistryLuca Giovanni Campana, Barbara Perić, Matteo Mascherini, Romina Spina, Christian Kunte, Erika Kis, Petra Rozsa, Pietro Quaglino, Maja Čemažar, Maša Omerzel, Gregor Serša, 2021, izvirni znanstveni članek Povzetek: Electrochemotherapy (ECT) is an effective locoregional therapy for cutaneous melanoma metastases and has been safely combined with immune checkpoint inhibitors in preliminary experiences. Since ECT is known to induce immunogenic cell death, its combination with immune checkpoint inhibitors might be beneficial. In this study, we aimed to investigate the effectiveness of ECT on cutaneous melanoma metastases in combination with pembrolizumab. We undertook a retrospective matched cohort analysis of stage IIIC%IV melanoma patients, included in the International Network for sharing practices of ECT (InspECT) and the Slovenian Cancer Registry. We compared the outcome of patients who received the following treatments: (a) pembrolizumab alone, (b) pembrolizumab plus ECT, and (c) ECT. The groups were matched for age, sex, performance status, and size of skin metastases. The local objective response rate (ORR) was higher in the pembrolizumab-ECT group than in the pembrolizumab group (78% and 39%, p < 0.001). The 1 year local progression-free survival (LPFS) rates were 86% and 51% (p < 0.001), and the 1 year systemic PFS rates were 64% and 39%, respectively (p = 0.034). The 1 year overall survival (OS) rates were 88% and 64%, respectively (p = 0.006). Our results suggest that skin-directed therapy with ECT improves superficial tumor control in melanoma patients treated with pembrolizumab. Interestingly, we observed longer PFS and OS in the pembrolizumab-ECT group than in the pembrolizumab group. These findings warrant prospective confirmation. Ključne besede: electrochemotherapy, metastatic melanoma, skin metastases Objavljeno v DiRROS: 10.10.2022; Ogledov: 464; Prenosov: 230 Celotno besedilo (701,05 KB) Gradivo ima več datotek! Več... |
48. Gene electrotransfer of IL-2 and IL-12 plasmids effectively eradicated murine B16.F10 melanomaTilen Komel, Maša Omerzel, Simona Kranjc Brezar, Mariangela De Robertis, M. Mastrodonato, G. Scillitani, G. Pesole, Emanuella Signori, Gregor Serša, Maja Čemažar, 2021, izvirni znanstveni članek Povzetek: Gene therapy has become an important approach for treating cancer, and electroporation represents a technology for introducing therapeutic genes into a cell. An example of cancer gene therapy relying on gene electrotransfer is the use of immunomodulatory cytokines, such as interleukin 2 (IL-2) and 12 (IL-12), which directly stimulate immune cells at the tumour site. The aim of our study was to determine the effects of gene electrotransfer with two plasmids encoding IL-2 and IL-12 in vitro and in vivo. Two different pulse protocols, known as EP1 (600 V/cm, 5 ms, 1 Hz, 8 pulses) and EP2 (1300 V/cm, 100 %s, 1 Hz, 8 pulses), were assessed in vitro for application in subsequent in vivo experiments. In the in vivo experiment, gene electrotransfer of pIL-2 and pIL-12 using the EP1 protocol was performed in B16.F10 murine melanoma. Combined treatment of tumours using pIL2 and pIL12 induced significant tumour growth delay and 71% complete tumour regression. Furthermore, in tumours coexpressing IL-2 and IL-12, increased accumulation of dendritic cells and M1 macrophages was obtained along with the activation of proinflammatory signals, resulting in CD4 + and CD8 + T-lymphocyte recruitment and immune memory development in the mice. In conclusion, we demonstrated high antitumour efficacy of combined IL-2 and IL-12 gene electrotransfer protocols in low-immunogenicity murine B16.F10 melanoma. Ključne besede: gene therapy, gene electrotransfer, IL-12, immunotherapy, melanoma Objavljeno v DiRROS: 23.09.2022; Ogledov: 586; Prenosov: 178 Celotno besedilo (4,12 MB) |
49. Biological factors of the tumour response to electrochemotherapy : review of the evidence and a research roadmapGregor Serša, Katja Uršič Valentinuzzi, Maja Čemažar, Richard Heller, Maša Omerzel, Luca Giovanni Campana, 2021, pregledni znanstveni članek Povzetek: The beneficial effects of electrochemotherapy (ECT) for superficial tumours and, more recently, deepseated malignancies in terms of local control and quality of life are widely accepted. However, the variability in responses across histotypes needs to be explored. Currently, patient selection for ECT is based on clinical factors (tumour size, histotype, and exposure to previous oncological treatments), whereas there are no biomarkers to predict the response to treatment. In this field, two major areas of investigation can be identified, i.e., tumour cell characteristics and the tumour microenvironment (vasculature, extracellular matrix, and immune infiltrate). For each of these areas, we describe the current knowledge and discuss how to foster further investigation. This review aims to provide a summary of the currently used guiding clinical factors and delineates a research roadmap for future studies to identify putative biomarkers of response to ECT. These biomarkers may allow researchers to improve ECT practice by customising treatment parameters, manipulating the tumour and its microenvironment, and exploring novel therapeutic combinations. Ključne besede: biological factors, biomarkers, electrochemotherapy, bleomycin, cisplatin Objavljeno v DiRROS: 23.09.2022; Ogledov: 520; Prenosov: 159 Celotno besedilo (1,32 MB) |
50. |